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Background. Previous studies indicate that fluorinated anesthet-
ics can enhance sphingomyelin (SM) hydrolysis in in vitro neuro-
nal extracts. Renal cortex has substantial SM content. Hence, this
study assessed whether in vivo fluorinated anesthetic use stimu-
lates renal SM hydrolysis, causing accumulation of ceramide, an
important signaling molecule.
Methods. Mice were anesthetized with isoflurane or desflurane
(fluorinated anesthetics). Pentobarbital anesthetized mice served
as controls. After six hours, kidney cortex was assayed for
ceramide. In selected experiments, renal cortical sphingosine and
sphingomyelinase (SMase) levels were also determined. Isoflu-
rane’s effects on ceramide levels in cultured human proximal
tubule (HK-2) cells/isolated mouse proximal tubule segments
(PTS), and on in vitro 14C-SM hydrolysis were also assessed.
Results. Isoflurane and desflurane, but not pentobarbital, in-
creased renal cortical ceramide levels (such as, 65% with isoflu-
rane, P , 0.003). Isoflurane also raised PTS/HK-2 ceramide levels
(by 25 to 35%). Ceramidase inhibition (fumonisin B1) did not
block this ceramide accumulation in HK-2 cells. Isoflurane did not
increase renal cortical/PTS SMase levels. However, it directly
enhanced the ability of (acidic) SMase to effect in vitro 14C-SM
hydrolysis. Isoflurane raised renal cortical sphingosine (and not
just ceramide) levels, implying ongoing ceramidase activity.
Conclusions. Fluorinated anesthetics can stimulate renal corti-
cal/tubule ceramide expression, presumably by stimulating
SMase-mediated SM hydrolysis. Since ceramide is a potential
mediator of tubule apoptosis/necrosis, these findings have poten-
tial relevance for the development of intra/post-operative acute
renal failure.
In recent years, there has been intense interest in the role
of sphingomyelin as a source of important cell signaling
molecules [1–6]. It is now well documented that when cells
are subjected to a number of physiologic or pharmacologic
influences (such as, TNFa, arachidonic acid, interleukin-1,
g interferon, vitamin D3, corticosteroids), plasma mem-
brane (neutral) and/or lysosomal (acidic) sphingomyeli-
nases are activated, resulting in sphingomyelin hydrolysis
[7–13]. This process yields phosphorylcholine and cer-
amide. The latter can then exert “second messenger”
functions, possibly via activation of ceramide-regulated
enzyme systems (for example, a phosphatase [14], a ceram-
ide-dependent kinase [15], and a stress-activated protein
kinase [16]). Protean alterations in cell homeostasis may
result, including changes in cell differentiation, altered cell
cycle progression, tissue inflammation, and apoptosis [1, 2,
5, 17, 18]. Ceramide can also undergo deacylation via
ceramidase(s), a process that generates additional signaling
molecules (sphingosine, sphingosine-1-phosphate). The lat-
ter may then exert direct actions (such as, protein kinase C
inhibition), or offset some of ceramide’s more proximate
effects [19–24]. These considerations underscore both the
complexity and protean potential influences of an activated
“sphingomyelinase pathway.”
In 1980, Pellkofer and Sandhoff reported that halothane,
a widely used fluorinated anesthetic, increases sphingomy-
elin hydrolysis when added to plasma membrane extracts
prepared from calf brain [25]. The underlying mechanism
was believed to be a drug-induced increase in membrane
fluidity, allowing brain-derived neutral sphingomyelinase to
increase its hydrolytic effect. Subsequent studies performed
by Mooibroek et al [26] indicated that this action was not
halothane specific, since three different fluorinated anes-
thetics (enflurane, methoxyflurane, as well as halothane)
stimulated sphingomyelin breakdown in cultured neuro-
blastoma cell extracts. The biological significance of these
interesting results have remained undefined for a number
of reasons: first, no attempts were made to ascertain
whether in vivo exposure to fluorinated anesthetics increase
cerebral sphingomyelin hydrolysis; second, the impact of
these agents on ceramide or sphingosine levels were not
assessed; and third, some of these in vitro results were
obtained with anesthetic dosages which exceeded a clini-
cally relevant range [26].
The kidney is relatively rich in sphingomyelin, compris-
ing ;13% of total cortical phospholipid content [27]. This
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raises the intriguing possibility that fluorinated anesthetics,
the current mainstay of anesthetic practice [28], might
activate an intra-renal sphingomyelinase pathway. In light
of ceramide’s diverse influences on cell homeostasis, such
an effect could potentially impact tubular responses to
renal hypoperfusion/ischemia or nephrotoxic drug expo-
sure, common events during a peri-operative period. Sup-
ports for such a possibility include: (1) the severity of
experimental ischemic and toxic ARF is critically depen-
dent on the type of anesthetic exposure [29, 30]; (2)
fluorinated anesthetics can exert either overt (such as,
methoxyflurane) or covert (isoflurane, desflurane, sevoflu-
rane) tubulotoxic effects [31–33]; and (3) two laboratories
have recently reported that cellular ceramide accumulation
can potentiate “chemical hypoxia” (antimycin A)-mediated
tubular cell death [34, 35].
Given these considerations, the current study was under-
taken to evaluate whether fluorinated anesthetics stimulate
renal sphingomyelinase activity, thereby altering renal cor-
tical concentrations of sphingomyelin-derived signaling
molecules. To address this possibility, mice were subjected
to general anesthesia with either fluorinated or nonfluori-
nated anesthetics and their impact on the “sphingomyeli-
nase cascade” was determined. In addition, direct fluorinated
anesthetic effects on in vitro renal cortical sphingomyeli-
nase activity was assessed.
METHODS
Anesthetic protocols
Male CD 1 mice (30 to 50 g; Charles River Laboratories,
Wilmington, MA, USA), maintained under standard viva-
rium conditions, were used for all experiments. They were
subjected to one of three anesthetic regimens, as described
below:
Isoflurane anesthesia. Isoflurane is the most widely used
of the inhalational fluorinated anesthetics [28]. Hence, it
was selected as the principal anesthetic for assessing in
vivo/in vitro sphingomyelinase activity. Nine mice (studied
in groups of 2 or 3) were placed in an air-tight 22 liter
anesthetic chamber [30]. Isoflurane was delivered with an
isoflurane-specific vaporizer to maintain a chamber isoflu-
rane concentration of 2.1% (monitored by infrared analyz-
er). This anesthetic concentration equates to 1.5 MAC, a
clinically relevant dosage [1 MAC (mean alveolar concen-
tration) is that concentration required to anesthetize 50%
of subjects] [28]. The isoflurane was delivered along with
100% oxygen at a flow rate of 2 liters/min. The mice were
kept on a 37°C heating blanket (temperature probe placed
between the mouse and the heating source). These anes-
thetic conditions maintained unconsciousness, caused no
mortality, and allowed for rapid recovery from anesthesia
within 3 to 5 minutes when removed from the anesthetic
chamber. After completing six hours of anesthesia, the
mice were removed from the chamber, and both kidneys
were rapidly excised through an abdominal incision (caus-
ing near immediate death by exanguination before recovery
from anesthesia). The kidneys were cooled (4°C), the renal
cortices dissected, and the tissues were snap frozen in liquid
nitrogen and stored at 270°C until processing for biochem-
ical analyses (see below). Nine normal mice provided
control renal cortical samples. These animals were anes-
thetized with pentobarbital (2 mg i.p.) just prior to kidney
resection, and the renal tissues were processed simulta-
neously with the tissues obtained from the isoflurane
treated animals.
Desflurane anesthesia. Isoflurane, like most fluorinated
anesthetics, undergoes cytochrome P450 metabolism, re-
leasing inorganic fluoride [28]. The latter can then exert
multiple biological effects [36]. To ascertain whether isoflu-
rane’s impact on the sphingomyelinase cascade is depen-
dent on inorganic fluoride release, additional experiments
were conducted as described above, substituting desflurane
for isoflurane anesthesia. Desflurane is structurally similar
to other fluorinated anesethetics, but it undergoes virtually
no defluorination [28, 30]. Six mice were anesthetized with
1.5 MAC of desflurane with a desflurane specific vaporizer
(8.5%, confirmed by infrared analysis; an equivalent anes-
thetic dose to the above isoflurane exposure). After com-
pleting a six hour exposure, the kidneys were rapidly
resected and processed, as noted above. Kidney samples,
obtained at the same time from 6 mice not subjected to
inhalational anesthesia (see above), provided control renal
cortical tissues.
Pentobarbital anesthesia. The following experment was
undertaken to ascertain whether the anesthetized state,
rather than the use of fluorinated anesthetics, per se, alters
the renal cortical sphingomyelin pathway. Six mice were
injected with pentobarbital (2 mg i.p.) and then they were
placed in the anesthetic chamber. They were maintained in
this chamber exactly as noted above, except for the absence
of an inhaled anesthetic. Repeated 0.5 mg doses of pento-
barbital were administered every 60 to 90 minutes as
needed to maintain six hours of anesthesia. After complet-
ing the anesthetic period, the kidneys were removed, and
the renal cortices were harvested and frozen for subsequent
analyses. Kidneys harvested from 6 mice, maintained under
routine laboratory conditions (except for pentobarbital
anesthesia immediately prior to kidney resection), provided
control renal cortical samples.
Ceramide assay
Ceramide was quantitated in renal cortical samples by
the bacterial diacylglycerol (DG) kinase assay of Younes et
al [37], as previously employed in this laboratory [34]. This
assay is based on the principle that ceramide (in addition to
diacylglycerol) is phosphorylated to ceramide-1-32P in the
presence of [g-32p] ATP. Hence, the amount of ceramide-
1-32P formed is directly and linearly related to the amount
of ceramide present in tissue extracts. In brief, renal
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cortical samples were homogenized in phosphate buffered
saline, the lipids were extracted in chloroform:methanol,
dried under N2, and then prepared for reaction with DG
kinase, as previously described in detail [34]. After com-
pleting the reaction, the 32P labeled ceramide was sepa-
rated from the rest of the lipids/reactants by thin layer
chromatography [34]. The plates were analyzed by autora-
diography, the ceramide-1-32P band was recovered by
scraping, and counted in a scintillation counter. The
amount of ceramide was calculated from a standard curve
constructed with type 3 ceramide standards (0 to 12.5 nmol;
from bovine brain). Values were expressed as pmol cer-
amide/nmoles phospholipid phosphate, the latter deter-
mined by the method of Van Veldhoven and Mannaerts
[38].
Sphingosine assay
An increase in tissue ceramide could result from either
increased ceramide production (such as, sphingomyelinase-
mediated sphingomyelin hydrolysis), or decreased cerami-
dase activity. The latter should be reflected by decreased
sphingosine concentrations (that is, decreased sphingosine
generation as a result of decreased deacylation of cer-
amide). To gain insights into which mechanism might be
operative in the fluorinated anesthetic-induced ceramide
increments (vide infra), sphingosine concentrations were
assessed. Tissue samples from 9 isoflurane-treated mice
and 7 control mice were analyzed for sphingosine using the
method of Merrill et al [39] as previously employed in this
laboratory [34]. In brief, the tissues were subjected to
chloroform:methanol extraction, the chloroform phase was
dried under N2, 0.2 M NaOH was added, and the free long
chain bases were recovered in chloroform. The samples
were dried and the free long chain bases were derivatized
with o-phthalaldehyde. The reactants were then separated
by HPLC (C18 column) [34] and analyzed with a spec-
trofluorometer. Sphingosine values were calculated from a
standard curve constructed with 0 to 500 pmole sphingosine
standards [34]. Sphinganine (500 pmoles) was added to the
sample to serve as an internal standard. Values were
expressed as fmoles sphingosine/nmol of sample phospho-
lipid phosphate.
Isoflurane effect on isolated proximal tubular segment
ceramide concentrations
The following experiment was undertaken to ascertain
whether isoflurane stimulates proximal tubular ceramide
accumulation, thereby suggesting that the results in whole
renal cortex reflected, at least in part, a direct proximal
tubular cell event. Isolated proximal tubular segments
(PTS), harvested from 5 normal mice by a previously
described technique [34], were each incubated for 60
minutes in 25 ml rubber stoppered Erlenmeyer flasks under
either normal oxygenation conditions (95% O2/5% CO2) or
under the same conditions except for the addition of 3.75 ml
of isoflurane (effecting ;1 mM aqueous isoflurane concen-
trations, as previously determined by gas chromatography)
[33]. After completing the 60 minute incubations with this
clinically-relevant anesthetic dose [33], the extent of cell
injury in the tubule preparations was determined by assess-
ing % lactate dehydrogenase (LDH) release, (using 100 ml
aliquots). The remaining samples were immediately centri-
fuged and the pellets processed for ceramide assay, as
above.
Isoflurane effects on ceramide levels in cultured
proximal tubular cells
HK-2 cells, an immortalized proximal tubule cell line
derived from normal human kidney, were grown in T75
flasks (N 5 9) with keratinocyte serum free medium (15
ml), as previously described [40]. After 72 hours in culture
(achieving near confluence), the flasks were stoppered with
rubber corks and divided into three treatment groups (N 5
3 each): (1) normal incubation conditions; (2) incubation
following the additon of 40 ml of isoflurane (added to the
260 ml flask by injecting through the stoppered cork); or (3)
40 ml of isoflurane 1 50 mM fumonisin B1 (FB1: a ceramide
synthase inhibitor) [34]. [Note: the pharmacologic rele-
vance of the employed gas isoflurane concentration is
indicated by the fact that it induces reversible anesthesia in
male CD-1 mice (unpublished data from this laboratory)].
After four hours of incubation under these conditions, the
flasks were iced, and the medium was decanted and cen-
trifuged. The cells in the flasks were then harvested by
adding 3 ml of Hank’s balanced salt solution, followed by
scraping with a rubber policeman. LDH was measured in
centrifuged cell culture media and in an aliquot of detached
pelleted cells in order to calculate % LDH. The remainder
of the cell samples were subjected to chloroform:methanol
extraction, the lipid phase was dried under N2, and then
samples were assayed for ceramide, as described above.
Effect of in vivo isoflurane exposure on renal cortical
sphingomyelinase levels
The following experiment assessed whether six hours of
isoflurane treatment leads to increases in renal cortical
sphingomyelinase levels, potentially explaining an increase
in ceramide production. To this end, renal cortical tissues,
collected from 11 normal mice and from 11 mice subjected
to six hours of isoflurane anesthesia, were assayed for
neutral and/or acidic sphingomyelinase levels (11 and 8
paired determinations for each enzyme, respectively). The
methods of Chatterjee and Ghosh [41] and Quintern and
Sandhoff [42] were used to determine neutral and acidic
sphingomyelinase, respectively, as previously employed by
this laboratory [43]. In brief, the tissues were minced,
washed, and homogenized in either an acidic or a neutral
lysis buffer [43]. The acidic and neutral enzyme prepara-
tions were centrifuged at 14,000 rpm and 1000 rpm, respec-
tively [41–43], and the supernatants were stored at 270°C
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until the time of assay. Both assays are based on the ability
of the acidic and neutral tissue protein extracts to effect in
vitro sphingomyelin hydrolysis (micelles prepared from
unlabeled 1 14C-labeled sphingomyelin) under either
acidic (pH 5), or neutral (pH 7.4) conditions, respectively.
Enzyme activities were expressed as nmoles of 14C-sphin-
gomyelin hydrolyzed/mg tissue protein extract/hr (that is,
14C-phosphorylcholine release from sphingomyelin). Of
note, these enzyme assays were conducted in the absence of
fluorinated anesthetics (that is, they assessed enzyme levels/
activity in the aftermath of anesthetic exposure).
Isoflurane effect on isolated proximal tubule segment
sphingomyelinase levels
Three sets of isolated proximal tubules were prepared, as
noted above, and they were incubated 3 60 minutes in
rubber stoppered 25 ml Erlenmeyer flasks, as noted above,
either under control oxygenated conditions or in the pres-
ence of 3.75 ml (;1 mM) isoflurane. After completing the
incubations, LDH release was determined and then the
tubules were pelleted, washed with Hank’s balanced salt
solution 32, and then extracted [43] and assayed for
neutral and acidic sphingomyelinase, as noted above.
Direct in vitro effect of isoflurane on renal cortical
sphingomyelinase activity
The following experiment was undertaken to ascertain
whether isoflurane can directly enhance sphingomyelinase-
mediated sphingomyelin hydrolysis. Normal mouse cortical
tissues were obtained (under brief pentobarbital anesthe-
sia) and extracted for acidic and neutral sphingomyelinase,
as noted above. These extracts were then used to determine
acidic and neutral sphingomyelinase activities (see above)
under one of three conditions (N 5 4 each): (1) normal
incubation conditions; (2) normal conditions except for 0.5
mM isoflurane addition; (3) normal conditions except for
1.0 mM isoflurane addition (clinically relevant aqueous
phase concentrations). The reactions were allowed to proceed
for 1.5 (acidic) or 2 (neutral) hrs and then sphingomyeli-
nase activities were determined (nmoles 14C-phosphoryl-
choline released from radiolabeled sphingomyelin/mg pro-
tein/hr, as noted above). Each isoflurane sample was run
simultaneously with a control sample obtained from the
same tissue homogenate.
Impact of isoflurane anesthesia on renal cortical heat
shock protein expression
The following experiment was undertaken to assess
whether six hours of isoflurane anesthesia induces a rela-
tively nonspecific “stress response.” If so, a change in
ceramide and sphingosine expression might reflect a non-
specific “stress” event, rather than a direct anesthetic
effect. To evaluate this possibility, a nonspecific renal
“stress response” was sought by probing renal cortical
tissues for heat shock protein (HSP) 72, which increases in
response to diverse forms of tissue damage [44–47]. Four
mice were subjected to six hours of isoflurane anesthesia.
Two mice were sacrificed immediately at the conclusion of
the anesthetic period. The remaining two mice underwent
an 18 hour post-anesthetic recovery period with free food
and water access. At the appropriate times, the mice were
anesthetized with pentobarbital, followed immediately
thereafter by renal resection. Cortical tissue were harvested
from these mice and from the following controls: negative
controls (2 mice maintained under normal laboratory con-
ditions); a positive control (a mouse subjected to glycerol-
induced myohemoglobinuria 24 hr earlier; 9 ml/kg 50%
glycerol i.m. injection) [30]. Renal cortical protein extracts
from these mice and Rainbow protein molecular wt mark-
ers (14.3 to 220 kD; Amersham, Arlington Hts., IL, USA)
were electrophoresed using a 4 to 20% Tris-glycine pre-cast
gel (#161-0903; BioRad, Hercules, CA, USA). The pro-
teins were transferred to nitrocellulose with a semi-dry
electroblotting technique. HSP 72 was probed with anti-
HSP 72 antibody (#1441–906; Boehringer Mannheim, In-
dianapolis, IN, USA/Mannheim, Germany). After washing,
the blots were reacted with a secondary mouse antibody
conjugated with horseradish peroxidase, followed by visu-
alization with 3,39-diaminobenzidine tetrahydrochloride
(Fast DAB; Sigma Chemicals, St. Louis, MO, USA).
Calculations and statistics
All values are presented as means 6 1 SEM. Statistical
comparisons were made by either unpaired or paired
Student’s t-test, as appropriate. Statistical significance was
taken as a P value of , 0.05.
RESULTS
Anesthetic effects on renal cortical ceramide
concentrations
As shown in Figure 1A, six hours of isoflurane anesthesia
caused an approximate 65% increase in renal cortical
ceramide concentrations, compared to nonanesthetic con-
trols (P , 0.003). A representative autoradiograph com-
paring control and isoflurane exposed kidney samples is
presented in Figure 2. As depicted in Figure 1B, desflurane
also induced a significant increase in renal cortical cer-
amide content. In contrast to the results obtained with
isoflurane and desflurane, mice subjected to six hours of
pentobarbital anesthesia failed to develop any significant
change in renal cortical ceramide concentrations, com-
pared to their paired nonanesthetic controls (Fig. 1C).
Isoflurane effects on renal cortical sphingosine
concentrations
Mice which were anesthetized for six hours with isoflu-
rane had renal cortical sphingosine levels of 273 6 17
fmol/nmol phospholipid phosphate. This was significantly
higher than values observed in control mice (202 6 17
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fmol/nmole phospholipid phosphate; P 5 0.016). Thus, the
anesthetic-induced alterations in sphingolipid metabolism
was not simply confined to altered ceramide content.
Isoflurane effects on renal cortical sphingomyelinase
activity
Sphingomyelinase levels in renal extracts from normal and
isoflurane anesthetized mice. As shown in Figure 3, tissue
extracts obtained from control and isoflurane treated mice
had virtually identical acidic (Fig. 3A) and neutral (Fig. 3B)
sphingomyelinase activities, as assessed by incubating tissue
extracts from these animals with exogenous 14C-labeled
sphingomyelin. [Note, this assay contained no isoflurane as
a reactant, since it rapidly vaporizes out of tissues. Hence,
this assay reflected the effects of six hours of in vivo
isoflurane exposure on renal cortical enzyme levels].
Direct effect of isoflurane on in vitro sphingomyelinase
activity. When normal kidney extracts were incubated with
14C-labeled sphingomyelin in the presence of 0.5 mM
iosoflurane, a 20% increase in acidic sphingomyelinase
activity resulted (P , 0.025; Fig. 4A). When this reaction
was conducted in the presence of 1.0 mM isoflurane, a
significant increase (25%) in acidic sphingomyelinase activ-
ity was, once again, observed (Fig. 4B). In contrast, neither
of these isoflurane dosages stimulated in vitro neutral
sphingomyelinase activity (Fig. 4B). This indicates the
relative specificity of the isoflurane - acidic sphingomyeli-
nase - sphingomyelin interaction.
Impact of isoflurane on proximal tubule segment
ceramide concentrations
After PTS isolation, they were subjected to a 15-minute
oxygenated rewarming period (from 4°C to 37°C), after
which baseline LDH release was 13 6 1%. Incubation of
the PTS for one hour under normal incubation conditions
(37°C) increased % LDH release to 21 6 1%. When these
one hour incubations were conducted in the presence of 1
mM isoflurane, no further increase in LDH release oc-
curred (22 6 1%), indicating an absence of overt isoflurane
cytotoxicity. However, these 60-minute isoflurane expo-
sures induced a significant increment in PTS ceramide
concentrations, rising by 25 6 5% above values observed in
their 60-minute co-incubated oxygenated controls (P ,
0.01; Fig. 5A).
Effect of transient isoflurane exposure on proximal
tubule segment sphingomyelinase levels
A one hour exposure to isoflurane failed to cause a
significant activation/increase in PTS sphingomyelinase ac-
tivities (that is, assessed in the absence of isoflurane).
Acidic sphingomyelinase values in PTS were 136 6 11 and
142 6 7 nmol/mg protein/hr for control and isoflurane
tubules, respectively (P 5 NS). Neutral values were 5.4 6
0.1 and 4.8 6 0.3 for control and isoflurane tubules,
Fig. 1. Renal cortical ceramide concentrations
in normal mouse kidneys and in kidneys
obtained from mice after six hours of isoflurane
(ISO; A; P < 0.0003), desflurane (DES; B; P <
0.0003), or pentobarbital (Pent; C; P 5 NS)
anesthesia. Isoflurane and desflurane, but not
pentobarbital, caused significant increases in
ceramide concentrations.
Fig. 2. Autoradiograph, obtained during ceramide assay. Lanes 1 and 2
are from control mice, and lanes 3 and 4 are from isoflurane treated mice.
The ceramide-132P bands (Cer) appear denser in the isoflurane samples
(with equivalent phospholipid phosphate loading for all samples). Note
that the ceramide-1-32P band appears as a doublet (due to differing acyl
group lengths (C16/C18 and C24 fatty acids). The whole band was cut and
counted together to quantitate total ceramide levels. PA 5 phosphatidic
acid.
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respectively (NS). The % LDH release for these tubules
after completing these 60 minute exposures were 23 6 3%
and 25 6 2% for control and isoflurane treated tubules,
respectively.
Isoflurane effects on HK-2 ceramide levels
Addition of isoflurane to cultured tubule cells induced a
33% increase in ceramide concentrations within a four
hours period (P , 0.05; Fig. 5B). This result was completely
unaffected by fumonisin B1 treatment (in a dose which has
previously been shown to inhibit HK-2 cell ceramide syn-
thase, as evidenced by a doubling of cell sphingosine
content; unpublished data from this laboratory). Isoflurane
treatment also caused a slight, but significant increase in %
LDH release (10.1 6 0.8% vs. 5.7 6 0.7%; isoflurane vs.
controls; P 5 0.013). This slight increment in % LDH
release was not diminished by FB1 treatment (11.0 6 0.9%;
P 5 0.01 vs. controls).
Assessment of renal cortical heat shock protein-72
expression
Normal mouse kidney manifested constituitive HSP-72
expression by Western blot analysis (Fig. 6, lanes 6 and 7).
Myohemoglobinuria induced a marked increase in HSP 72
levels, assessed 24 hours post-glycerol injection (lane 1;
serving as a positive control). Neither six hours of isoflu-
rane anesthesia (lanes 2 and 3) nor six hours of isoflurane
Fig. 3. Sphingomyelinase activity in cortical
tissue extracts obtained from isoflurane
anesethetized (ISO) and control mice. There
were no significant differences in either acidic
(A) or neutral (B) enzyme activities, indicating
that the isoflurane-induced ceramide
increments were not a result of increased
enzyme levels.
Fig. 4. Effects of isoflurane additions (0.5 and
1.0 mM) on sphingomyelinase activity in cell
free extracts. Both doses of isoflurane induced
an approximate 20 to 25% increase in acidic
sphingomyelinase-mediated 14C-sphingomyelin
breakdown. However, neither isoflurane dosage
stimulated neutral sphingomyelinase activity
(indicating the relative specificity of the acidic
sphingomyelinase result).
Fig. 5. Ceremide in proximal tubular segments (A) and in cultured
tubular (HK-2) cells (B). (A) Ceramide concentrations in isolated PTS
incubated for one hour under control oxygenated conditions or in the
presence of 1 mM isoflurane. Isoflurane induced significant ceramide
increments. (B) When HK-2 cells were incubated with isoflurane for four
hours, a 33% increase in ceramide concentrations resulted. This result was
not impacted by ceramide synthase inhibition (fumonisin B1; FB1),
indicating that it was not secondary to de novo ceramide synthesis.
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plus an 18 hours post-anesthetic recovery period noticeably
altered HSP 72 expression (lanes 4 and 5). (Of note, that
HSP-72 was observed in the normal kidneys indicates that
the failure to observe an increase with isoflurane treatment
was not due to insufficient sensitivity of the employed
Western blot).
DISCUSSION
It is widely recognized that the immediate post-operative
period is a common time for the onset of acute renal failure
(ARF). Despite this fact, the impact of anesthetics on renal
tubular cell homeostasis, and their potential for altering
tubular responses to injury, have received surprisingly little
attention. Fluorinated hydrocarbons (isoflurane, enflurane,
sevoflurane, halothane, desflurane) are the most commonly
used class of general anesthetics, and evidence exists that
they can impact tubular cell metabolism. First, methoxyflu-
rane, a prototype of this class of agents, is overtly nephro-
toxic, having caused multiple cases of post-operative ARF
cases in the 1960s and 1970s [31, 32]. Second, isoflurane,
the most commonly used fluorinated anesthetic, induces
both proximal tubular enzymuria in surgical patients and
lethal cell injury to isolated proximal tubule segments [33].
Third, fluorinated anesthetics can negatively impact both
tubular energy consumption and production by inhibiting
Na,K-ATPase and mitochondrial respiration, respectively
[33]. Fourth, cytochrome p450 metabolism of fluorinated
anesthetics liberates inorganic fluoride which can then
induce either dose dependent cytotoxic [33], or paradoxi-
cal, cytoprotective effects [30, 36].
The results of the present experiments indicate that an
additional influence of fluorinated anesthetics on renal
homeostasis is an increase in cortical ceramide content.
After six hours of in vivo isoflurane anesthesia, a 65%
increase in renal cortical ceramide levels resulted. The
origin of the ceramide was almost certainly the kidney,
since ceramide’s highly lipophilic nature makes its release
into the systemic circulation, with subsequent intra-renal
accumulation, highly unlikely. That a comparable length
and depth of anesthesia with pentobarbital, a nonfluori-
nated anesthetic, caused absolutely no renal ceramide
increments indicates that the isoflurane-induced ceramide
accumulation was not simply a secondary, non specific,
manifestation of the anesthetized state. As noted above,
many fluorinated anesthetic effects have been mechanisti-
cally linked to cytochrome p450 mediated inorganic fluo-
ride release [28]. However, when mice were anesthetized
with desflurane, a drug which releases virtually no inorganic
fluoride [28, 30], significant renal cortical ceramide accu-
mulation, once again, resulted. Thus, these findings: (1)
represent the first demonstration in any organ that clini-
cally relevant fluorinated anesthetic exposures increase in
vivo tissue concentrations of sphingomyelin derived-signal-
ing molecules; and (2) indicate that this change can be
largely dissociated from anesthetic inorganic fluoride re-
lease.
The renal cortical cell type(s) (such as, glomerular,
vascular, tubular) that participated in these in vivo cer-
amide accumulations remain unknown. However, that
isoflurane induced ;25% and ;35% ceramide increments
in freshly isolated mouse proximal tubular segments and
cultured human kidney (HK-2) cells, respectively, indicates
that the proximal tubular epithelium was almost certainly
involved. The PTS and HK-2 cell data also indicate that the
in vivo ceramide increments likely reflected a direct drug/
kidney interaction, since these models could not have been
influenced by potential systemic or hemodynamic conse-
quences of fluorinated anesthetic use. That six hours of
isoflurane anesthesia triggered ceramide increments in the
absence of increased renal cortical HSP expression further
serves to dissociate the ceramide changes from a non
specific “stress response” to general anesthesia.
Four conceivable mechanisms exist by which fluorinated
anesthetics might increase tissue ceramide content: (i)
increased ceramide synthesis; (ii) decreased ceramide
breakdown; (iii) increased sphingomyelinase levels; or (iv)
a drug induced increase in membrane susceptibility to
sphingomyelinase-mediated attack. The available data
Fig. 6. Western blot demonstrating heat shock
protein 72 (HSP 72) expression in cortical
tissue extracts. Lane 1, myohemoglobinuria-
induced positive control; lanes 2 and 3, six
hours of isoflurane anesthesia; lanes 4 and 5,
six hours of isoflurane 1 18 hours of recovery;
lanes 6 and 7, normal mouse kidneys.
Isoflurane did not noticeably increase HSP 72
levels above normal levels.
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strongly suggest the fourth possibility. First, when cultured
tubular cells were challenged with isoflurane in the pres-
ence or absence of fumonisin B1, identical increments in
ceramide resulted. This seemingly excludes de novo synthe-
sis as the cause of ceramide acumulation. Second, since
sphingosine is the immediate downstream product of cer-
amidase activity, documentation that isoflurane treatment
increases both sphingosine and ceramide concentrations
argues against an in vivo ceramidase blockade. Third, renal
cortical extracts obtained from control and isoflurane
treated mice had essentially identical acidic and neutral
sphingomyelinase levels. Similarly, isoflurane did not in-
crease PTS sphingomyelinase levels following isoflurane
exposure. Thus, these results indicate that these agents do
not simply induce a fixed increase in enzyme levels, thereby
enhancing sphingomyelin hydrolysis. Finally, when sphin-
gomyelin- containing micelles were challenged in vitro with
a fixed amount of sphingomyelinase in the presence of
isoflurane, dose dependent increments in 14C-sphingomye-
lin hydrolysis resulted. This indicates that although isoflu-
rane does not induce new enzyme, it is able to increase the
ability of pre-existent enzyme to effect sphingomyelin hy-
drolysis. Indeed, this is consistent with the known capability
of fluorinated anesthetics to increase membrane fluidity,
which then sensitizes membrane bound sphingomyelin to
sphingomyelinase-mediated attack [25, 26]. It is noteworthy
that under these conditions, isoflurane only stimulated
acidic (lysosomal), and not neutral (plasma membrane),
sphingomyelinase-induced hydrolysis. This indicates the
relative specificity of the acidic sphingomyelinase result,
and implies that the intracellular origin of the isoflurane-
induced cortical ceramide increments is likely the lyosomal
compartment. In contrast to kidney, fluorinated anesthetics
have been reported to stimulate neutral sphingomyelinase-
mediated sphingomyelin hydrolysis in neuronal tissues [25,
26]. While the reason for this discrepancy between neuro-
nal and renal tissues is unknown, it does imply that tissue
specific differences in anesthetic effects on sphingomyeli-
nase-substrate interactions exist.
While the present studies support the concept that
fluorinated anesthetics can enhance sphingomyelin hydro-
lysis, thereby raising renal ceramide and sphingosine levels,
the potential relevance of these observations remains to be
defined. However, studies suggest the possibility that they
could impact the expression of acute renal failure, as
follows: (1) ceramide and sphingosine can initiate either
apoptotic [5, 35, 48] or necrotic [49] tubular cell death,
processes critical to ARF; (2) when an otherwise sublethal
amount of ceramide is added to ATP-depleted tubular
cells, increased cell death results [34, 35]; (3) ceramide can
foster tubular cell detachment [34], an important patho-
physiologic event during the induction phase of ARF [50];
(4) ceramide can also stimulate epidermal growth factor
receptor phosphorylation [15], potentially impacting post-
tubular injury recovery events; and (5) when tubular cells
are exposed to subtoxic sphingosine concentrations, ‘ac-
quired cytoresistance’ [49], a hallmark of the early mainte-
nance phase of ARF, develops [46, 51]. Finally, it is
noteworthy that, in the present experiments, a four hour
exposure to a pharmacologically relevant dose of isoflurane
caused a slight (5%), but significant, increase in HK-2 cell
death. Similarly, clinically relevant isoflurane doses trigger
cell death in isolated PTS [33]. While these latter results
may not necessarily be mechanistically linked to ceramide
generation per se, they do serve to underscore the potential
of fluorinated anesthetics to directly impact proximal tubu-
lar homeostasis.
In conclusion, the present experiments provide the first
evidence that in vivo exposure to fluorinated anesthetics
can enhance renal cortical concentrations of ceramide and
sphingosine, important second messengers within the
sphingomyelin signaling cascade. The data are consistent
with the hypothesis that this occurs via a drug induced
enhancement of sphingomyelinase-mediated sphingomye-
lin hydrolysis. To our knowledge, this is the first demon-
stration that fluorinated anesthetics can induce this action
on any in vivo tissue. While the ultimate pathophysiologic
impact of these observations remain unknown, the well
accepted role of ceramide as a determinant of cell viability
under conditions of tissue stress suggest potential relevance
for the development of early post-operative ARF.
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